Probiotic supplementation in healthy full-term infants is associated with increased faecal secretory IgA (sIgA), an antibody that lines the gut, with effects strongest when started by 4 weeks of age . Effects on broader immune markers remain unclear.
Researchers conducted a systematic review and meta-analysis of 39 randomised controlled trials examining how probiotic supplementation affects infant immune development. The question matters because the infant gut microbiome is rapidly developing in the first months of life, and this period is thought to be critical for immune training. However, researchers noted that while probiotics influence early immune development, the specific immune changes they produce have remained poorly understood.
For the primary outcome, faecal secretory IgA (sIgA), the team focused their quantitative analysis on the most homogeneous population: healthy full-term infants without illness or complications. Seven trials met criteria for this analysis, involving 440 infants receiving probiotics and 414 controls. The pooled result was clear: probiotic supplementation was associated with a mean increase of 435 micrograms per gram of stool (95% CI 196-674 micrograms/g). The confidence interval excludes zero, and heterogeneity was negligible (I² = 0%), indicating consistency across studies. Importantly, larger increases in sIgA were observed when probiotic supplementation began at or before 4 weeks of age compared to later initiation, suggesting a time-sensitive window.
The secondary outcome, cytokine responses, painted a different picture. Eighteen trials reported cytokine measurements, but these came from clinically diverse populations including infants with infections, allergic symptoms, or other conditions. The researchers attempted pooled analyses but found no consistent effects across cytokines. This lack of consistency likely reflects both the heterogeneity of study populations and the complexity of cytokine signalling, where local gut effects may not translate to measurable changes in stool cytokines. The team explicitly noted this limitation, stating that cytokine outcomes derived from "more clinically heterogeneous populations" did not show reliable patterns.
The analysis included sensitivity checks: the sIgA estimate remained robust when studies were removed individually, and the direction and magnitude of effect persisted across different analytical approaches. Risk of bias assessment using the RoB 2 tool was conducted for all included trials, though specific bias patterns are not detailed in the abstract provided.
Secretory IgA is one piece of infant immune function. The study demonstrates an association between probiotics and a specific immune marker in healthy infants, but sIgA is a mechanism, not a health outcome. Higher sIgA means the gut has more antibodies coating its surface, which theoretically supports mucosal defence. Whether this translates to reduced infections, better health outcomes, or altered disease risk remains unanswered by this evidence.
The timing signal is worth noting. If considering probiotics for a healthy infant, early initiation (within the first month) showed larger sIgA responses than later introduction. This aligns with the broader biology of immune window theory, though it doesn't establish clinical necessity.
Broader immune effects remain uncertain. The absence of consistent cytokine findings suggests that probiotics do not produce uniform immune activation across measured inflammatory markers. This is neither surprising nor concerning, as local gut effects and systemic cytokine changes operate through different mechanisms.
This is mechanistic data, not efficacy data. The study establishes that a biomarker changes; it does not demonstrate that probiotics reduce infection rates, improve digestive health, or prevent disease in healthy infants. Parents and clinicians should distinguish between demonstrated mechanisms and proven clinical benefits.
| Parameter | Details |
|---|---|
| Study type | Systematic review and meta-analysis |
| Trials included | 39 RCTs; 7 for primary sIgA analysis in healthy full-term infants |
| Population | Infants up to 2 years of age; primary analysis restricted to healthy full-term infants |
| Sample size (sIgA analysis) | 440 probiotic, 414 control |
| Primary outcome | Faecal secretory IgA (sIgA) |
| Secondary outcome | Cytokines |
| Main finding | 435 micrograms/g stool difference (95% CI 196-674); I² = 0% |
| Time-dependent effect | Larger sIgA increases with supplementation at or before 4 weeks of age |
| Heterogeneity | Low (I² = 0%) for sIgA in healthy full-term cohort |
| Databases searched | Six major databases, 2000-2025 |
| Risk of bias tool | RoB 2 |
| Journal | Pediatric Research |
| PubMed ID |
Penders J, et al. (2025). Probiotic supplementation is associated with higher faecal secretory IgA (sIgA) in healthy full-term infants: a systematic review and meta-analysis. *Pediatric Research*. PubMed: 42174205
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.